文献速递脑血管病认知障碍与痴呆

散发性和遗传性脑淀粉样血管病中脑脊液淀粉样β蛋白38、40、42和43水平降低

Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
PubMed 文献 · Ann Neurol · 2023-02-20

该研究通过免疫分析检测发现组、验证组及遗传性荷兰型脑淀粉样血管病(D-CAA)组的脑脊液淀粉样β蛋白(Aβ)38、40、42和43水平,发现散发性脑淀粉样血管病(sCAA)和D-CAA患者上述肽段水平较对照组降低,其中Aβ42和Aβ43对sCAA与对照的鉴别AUC最高;除Aβ43外其他肽段在sCAA与阿尔茨海默病(AD)间也有差异。

要点

  • sCAA和D-CAA患者脑脊液Aβ38、Aβ40、Aβ42、Aβ43水平均较对照组降低。
  • sCAA与对照鉴别时Aβ42的AUC发现组0.90、验证组0.94,Aβ43的AUC发现组0.95、验证组0.91。
  • sCAA与AD鉴别时除Aβ43外其他Aβ肽段降低,Aβ38、Aβ40、Aβ42的AUC分别为0.82、0.88、0.79。

核心结论

  • 脑脊液Aβ38、Aβ40、Aβ42和Aβ43联合生物标志物组合有潜力区分sCAA与AD及对照,以及区分D-CAA与对照。

研究设计与样本

  • 免疫分析定量脑脊液Aβ肽段,包括发现组(26例sCAA和40例对照)、验证组(40例sCAA、40例AD和37例对照)以及22例D-CAA和54例对照。
  • 通过受试者工作特征曲线计算曲线下面积(AUC)及95%置信区间(CI)以确定诊断准确性。

主要发现

  • sCAA患者和D-CAA患者所有Aβ肽段水平均较对照组降低。
  • sCAA与对照比较,Aβ42的AUC发现组为0.90(95% CI=0.82-0.99),验证组为0.94(95% CI=0.89-0.99);Aβ43的AUC发现组为0.95(95% CI=0.88-1.00),验证组为0.91(95% CI=0.83-1.0)。
  • sCAA与AD比较,除Aβ43外所有Aβ肽段降低,脑脊液Aβ38的AUC=0.82(95% CI=0.71-0.93),Aβ40的AUC=0.88(95% CI=0.80-0.96),Aβ42的AUC=0.79(95% CI=0.66-0.92)。

关键数值与推荐

  • sCAA与对照鉴别:Aβ42发现组AUC 0.90(95% CI=0.82-0.99)、验证组AUC 0.94(95% CI=0.89-0.99);Aβ43发现组AUC 0.95(95% CI=0.88-1.00)、验证组AUC 0.91(95% CI=0.83-1.0)。
  • sCAA与AD鉴别:脑脊液Aβ38 AUC=0.82(95% CI=0.71-0.93),Aβ40 AUC=0.88(95% CI=0.80-0.96),Aβ42 AUC=0.79(95% CI=0.66-0.92)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vascular amyloid β (Aβ) accumulation is the hallmark of cerebral amyloid angiopathy (CAA). The composition of cerebrospinal fluid (CSF) of CAA patients may serve as a diagnostic biomarker of CAA. We studied the diagnostic potential of the peptides Aβ38, Aβ40, Aβ42, and Aβ43 in patients with sporadic CAA (sCAA), hereditary Dutch-type CAA (D-CAA), and Alzheimer disease (AD). METHODS: Aβ peptides were quantified by immunoassays in a discovery group (26 patients with sCAA and 40 controls), a validation group (40 patients with sCAA, 40 patients with AD, and 37 controls), and a group of 22 patients with D-CAA and 54 controls. To determine the diagnostic accuracy, the area under the curve (AUC) was calculated using a receiver operating characteristic curve with 95% confidence interval (CI). RESULTS: We found decreased levels of all Aβ peptides in sCAA patients and D-CAA patients compared to controls. The difference was most prominent for Aβ42 (AUC of sCAA vs controls for discovery: 0.90, 95% CI = 0.82-0.99; for validation: 0.94, 95% CI = 0.89-0.99) and Aβ43 (AUC of sCAA vs controls for discovery: 0.95, 95% CI = 0.88-1.00; for validation: 0.91, 95% CI = 0.83-1.0). All Aβ peptides except Aβ43 were also decreased in sCAA compared to AD (CSF Aβ38: AUC = 0.82, 95% CI = 0.71-0.93; CSF Aβ40: AUC = 0.88, 95% CI = 0.80-0.96; CSF Aβ42: AUC = 0.79, 95% CI = 0.66-0.92). INTERPRETATION: A combined biomarker panel of CSF Aβ38, Aβ40, Aβ42, and Aβ43 has potential to differentiate sCAA from AD and controls, and D-CAA from controls. ANN NEUROL 2023;93:1173-1186.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. De Kort AM, Kuiperij HB, Marques TM, et al. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy. Ann Neurol. 2023. PMID: 36707720. doi:10.1002/ana.26610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。